Source link : https://newshealth.biz/health-news/next-gen-serd-cuts-breast-cancer-recurrence-risk-by-30-in-trial/
(MedPage Today) — SAN ANTONIO — In a large phase III trial of adjuvant treatment for early-stage breast cancer, the investigational oral drug giredestrant reduced the risk of invasive disease recurrence by 30% versus standard endocrine therapy… Source link : https://www.medpagetoday.com/meetingcoverage/sabcs/118944 Author : Publish date : 2025-12-10 22:45:00 Copyright for syndicated content belongs to the […]
The post Next-Gen SERD Cuts Breast Cancer Recurrence Risk by 30% in Trial first appeared on News Health.
—-
Author : News Health
Publish date : 2025-12-10 22:45:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8